

Johnson & Johnson Innovative Medicine
Hematology Request for Proposals

Johnson & Johnson Innovative Medicine is pleased to announce a Request for Proposals (RFP) focused on supporting implementation science–driven initiatives within community-based health care organizations aimed at optimizing the treatment and care of patients with relapsed/refractory multiple myeloma (RR/MM) who may be eligible for chimeric antigen receptor (CAR) T-cell therapy.

The overarching goal of this initiative is to support the application of evidence-based practices through harmonized educational, operational, and collaborative strategies. Successful proposals will demonstrate how education is embedded within broader implementation efforts and how these combined approaches lead to measurable improvements in care processes, clinician behavior, and patient outcomes for individuals with RR/MM.

The Implementation Science grants are intended to support projects aimed at improving patient outcomes in areas where medical needs are not fully met. **These are different from general research grants, which primarily focus on generating new knowledge and evidence through systematic investigation.**

Under this RFP, projects should focus on implementing and evaluating practice-level or system-level changes and embedding certified education (CME/CE) to facilitate adoption, appropriate use, and sustainability of evidence-based care.

It is the expectation that findings from your project will be disseminated to the healthcare community via posters, abstracts, white papers, publications, or similar scholarly professional communications.

The implementation science grants fall under the auspices of independent medical education. Accordingly, Johnson & Johnson will have **no control or influence** over the design or conduct of funded projects, the content of educational activities, or the selection of faculty or authors.

Research projects are out of scope for this RFP and will not be considered.

Grant Application Deadline: July 15, 2026

Therapeutic Area: Relapse/Refractory Multiple Myeloma

Overview:

Grants awarded under this RFP will prioritize initiatives in which certified education is intentionally embedded within broader implementation and care delivery strategies, rather than serving as a standalone or ancillary activity. The review committee is specifically seeking initiatives that focus on community practices, identify real-world barriers contributing to clinical inertia or suboptimal care delivery, and implement actionable strategies—integrated with

education—to drive behavior change, process improvement, and sustained adoption of evidence-based practices.

Proposals should describe the operational and process-based changes that will be implemented, including how cross departmental and cross functional teams (e.g., hematology/oncology, pharmacy, nursing, care coordination, administration) will be engaged to support improved patient access to and management before, during, and after CAR T-cell therapy (e.g., referral coordination, bridging therapy planning, toxicity monitoring and follow-up, and transition of care back to the community setting).

Proposals also need to clearly articulate the certified educational components (CME/CE) to be leveraged, including the target learner audience(s), educational format(s), content focus, learning objectives, and how these interventions are designed to address identified barriers to optimal care and treatment implementation. They should describe how the educational interventions will be aligned with and reinforce practical changes within the cancer center or health system to improve access to and appropriate use of CAR T-cell therapies by community clinicians. Proposals should define clear success metrics and describe how both implementation strategies and educational components will be evaluated for impact.

Projects of Interest:

- Creating mentorship models, peer to peer networks or collaborations, connecting experienced CAR T centers/clinicians with community clinicians to offer guidance and mentorship using flexible engagement modalities tailored to the community clinician's needs such as:
 - Establishing best practices for patient selection/referral to local CAR-T centers
 - Improving AE monitoring/mitigation strategies at the community level
 - Establishing communication strategies/protocols with local/referring centers, including workflows for transition of care
 - Providing staff training & multidisciplinary coordination to support safe and effective use
 - Establishing processes and protocols for monitoring and managing treatment-related side effects
 - Increasing patient education to support shared decision making and participation in their care
- Integrating novel technologies for remote monitoring

Applicants must demonstrate how the implemented changes will be sustained beyond the grant period. If collaborating with multiple institutions, please include letters of commitment from all parties.

Target Audience:

Community Hematologist/Oncologists, Academic Hem/Oncs (to serve as mentors to community practices)

Eligibility Criteria:

This RFP is open to community cancer centers and healthcare institutions with experience in treating multiple myeloma. Collaborative proposals involving multiple institutions or disciplines are highly encouraged. **Eligible applicants include academic institutions (medicine, pharmacy, nursing), teaching hospitals, medical societies or professional associations, government agencies, and medical education companies.**

Interested clinicians are encouraged to work closely with their institution's office of Continuing Medical Education or an ACCME accredited organization and **not their research departments.** Requests must be certified for CME/CE credit(s) and the **grant application/request must be submitted by the accredited organization.**

Clinicians at community cancer centers without an internal CME office may partner with an ACCME-accredited medical society, professional association, or medical education company to develop the proposal and submit the grant application

Research grants will not be accepted.

Project Timelines:

Programs start date should be on or after September 1, 2026 and can run up to 18 months.

Funding Limits:

Up to \$275,000, lower cost projects will be prioritized. Grant payments will be made in full.

Institutional overhead, salaries, and durable medical equipment are not permitted.

Project Deliverables/Final Report:

Grantees will be expected to provide quarterly project updates throughout the duration of the project. Upon conclusion of the project, grantees are required to submit a comprehensive final report that documents the implemented changes and educational activities; educational reach, engagement and participation, and the resulting impact. At a minimum, the final report must include:

- Learner and participation metrics, including reach, engagement, and completion of the certified educational activities
- Educational outcomes, such as changes in learner knowledge, competence, confidence, or intent to change practice, as appropriate to the design of the activity
- Clinician behavior and practice level changes, including adoption of new workflows, protocols, decision support tools, or care processes related to bispecific antibody use
- System or process outcomes, such as improvements in care coordination, patient identification, treatment initiation, monitoring, or management of therapy related adverse events
- Patient level or population level outcomes, where feasible and appropriate, including measures of access, quality of care, or care delivery efficiency

- Sustainability considerations, describing how implemented changes will be maintained beyond the grant period

Outcomes should be measured using prespecified metrics and evaluation methodologies that align with the project’s stated goals and objectives and reflect higher level outcomes consistent with Moore’s framework for outcomes assessment. A final budget reconciliation is also required at the conclusion of the project.

Review Process:

A formal grant review process will be utilized by the grant review committee to determine all final decisions. Grant applicants will be notified via email of the final decision. If information is missing or the committee needs additional information, you will be notified during the review process.

Any questions related to this RFP can be submitted to akaczers@its.jnj.com, with “IS RRMM BSAB 2026” in the subject line. For questions related to the setting up a user account, grant submission and the Cybergrants portal, please click “**need support**” on bottom of the Cybergrants log in page.

Submission Link: <https://www.cybergrants.com/JJ/grantsandgiving>

Special Notes: In the grant submission, please be sure to select “yes” to the question, is this in response to an RFP. In the RFP title, please use “IS CAR T 2026.” Please also include “IS CAR T 2026” in your proposal title.

Proposal Requirements:

The following elements are necessary to be considered for a grant review. Please familiarize yourself with the grant application prior to submitting your grant. (A list of FAQ’s can be found at the following link, please be sure to scroll through to the bottom: [Johnson & Johnson](#))

Elements	Description
Goals and Objectives	Summarize the main goals of the project, explain how it supports the priorities of the funding announcement and your organization, and clearly outline the learning and outcome objectives, specifying the intended audience and the changes or results you expect to achieve.
Assessment of Need	Summarize the current challenges and gaps related to CAR T therapy in <i>your</i> center. Present current quantitative data or baseline metrics that highlight the need for the project, referencing gap analyses or relevant patient data. Explain where and how the data was collected, how it was analyzed to identify the need, and, if data collection is ongoing, outline your plan for gathering and analyzing

	this information.
Target Audience	Identify the main group(s) the project is designed to reach and the number of participants within your Improvement project. Provide information on the total population your project is serving.
Project Design	Detail the approach you will take to address the identified need, including the educational components, and briefly describe the topics and formats of the planned educational activities. In your proposal explain the potential changes/action steps/or other measures you may take. If applicable, explain how this project may leverage previous efforts shared by other institutions.
Timelines	Include an anticipated timeline of your project, with the intention to complete your project within 18 months.
Outcomes	Explain the methodology that will be applied to determine the impact of the project. How will the data be analyzed
Budget	A detailed budget is required for all grant applications. Institutional overhead/fees are not permitted with these grant requests. Educational grants cannot support salaries or DME.